144035-83-6 Usage
Description
3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide, also known as Piclamilast, is a monocarboxylic acid amide derived from the formal condensation of the carboxy group of 3-(cyclopentyloxy)-4-methoxybenzoic acid with the primary amino group of 3,5-dichloropyridin-4-amine. It is a potent and selective phosphodiesterase-4 (PDE4) inhibitor, which makes it a promising candidate for various therapeutic applications.
Uses
Used in Respiratory Disease Treatment:
3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide is used as a therapeutic agent for respiratory diseases, particularly asthma and chronic obstructive pulmonary disease (COPD). It works by inhibiting PDE4, which leads to the reduction of inflammation and improved lung function in patients suffering from these conditions.
Used in Pre-term Infant Treatment:
In the medical field, 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide is used as a treatment option for pre-term infants with bronchopulmonary dysplasia (BPD). Its PDE4 inhibitory properties help in managing the symptoms and improving the overall health of these infants.
Used in Pharmaceutical Industry:
3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide is used as a key compound in the development of new drugs targeting various diseases, including respiratory and inflammatory conditions. Its potent PDE4 inhibitory activity makes it a valuable asset in the pharmaceutical industry for creating innovative therapeutic solutions.
Check Digit Verification of cas no
The CAS Registry Mumber 144035-83-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,4,0,3 and 5 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 144035-83:
(8*1)+(7*4)+(6*4)+(5*0)+(4*3)+(3*5)+(2*8)+(1*3)=106
106 % 10 = 6
So 144035-83-6 is a valid CAS Registry Number.
InChI:InChI=1/C18H18Cl2N2O3/c1-24-15-7-6-11(8-16(15)25-12-4-2-3-5-12)18(23)22-17-13(19)9-21-10-14(17)20/h6-10,12H,2-5H2,1H3,(H,21,22,23)
144035-83-6Relevant articles and documents
Cancer treatment method
-
, (2008/06/13)
The invention relates to a method for treating cancer including administering to a mammal therapeutically effective amounts of an anti-neoplastic agent and a PDE4 inhibitor, treatment combinations containing the same as well as a method for attenuating unwanted cancer treatment side effects including myelosuppression and mucositis.
Process development of the PDE IV inhibitor 3-(cyclopentyloxy)-n-(3,5-dichloropyrid-4-yl)-4-methoxybenzamide
Cook, David C.,Jones, Ronald H.,Kabir, Humayun,Lythgoe, David J.,McFarlane, Ian M.,Pemberton, Clive,Thatcher, Alan A.,Thompson, David M.,Walton, John B.
, p. 157 - 168 (2013/09/08)
Development of an industrial process for 3-(cyclopentyloxy)-N-(3,5-dichloropyrid-4-yl)-4-methoxybenzamide, a potent PDE IV type inhibitor, is described. The rapid identification of scalable reaction conditions allowed pilot-scale synthesis of kilogramme quantities for early clinical evaluation. However, as more compound was demanded, better reaction conditions were required in the interests of safety, economics, and environmental impact. This led to the derivation of a high-yielding and very robust procedure which included various safeguards to ensure that high-quality product was obtained and that new trace impurities were effectively removed. The large-scale oxidation of a benzaldehyde derivative to the corresponding benzoic acid using hydrogen peroxide under aqueous alkaline conditions is described.
Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
-
, (2008/06/13)
This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.
